tislelizumab + S-1

Tislelizumab + S-1 is a combination therapy consisting of tislelizumab, a humanized IgG4 monoclonal antibody targeting programmed death-1 (PD-1), and S-1, an oral fluoropyrimidine-based chemotherapy agent. Tislelizumab blocks the PD-1 receptor on T cells, preventing its interaction with PD-L1 and thereby enhancing anti-tumor immune responses by restoring T cell activity. S-1 combines tegafur (a prodrug of 5-fluorouracil) with two modulators to enhance efficacy and reduce gastrointestinal toxicity. This combination is being investigated primarily for the treatment of locally advanced or recurrent cancers such as esophageal squamous cell carcinoma (ESCC) and intrahepatic cholangiocarcinoma, particularly in elderly or high-risk patients[1][4]. The rationale for combining these agents is to leverage both immunotherapy-mediated tumor recognition and cytotoxic chemotherapy effects.

Brand names

TevimbraTigioTS-1TS1TS 1

Other names

Arm A-Tianjin Medical University Cancer Institute and Hospital-esophageal squamous cell carcinomatislelizumab + tigiotislelizumab + tegafur + gimeracil + oteracil